|
Market Closed -
Swiss Exchange
16:30:07 28/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 73.40 CHF | +1.66% |
|
+8.74% | +34.19% |
| 10-27 | Basilea Pharmaceutica Lifts FY26 Guidance | MT |
| 10-27 | Basilea raises full-year guidance 2026 and financial target for "Agenda 2030" and provides updates on late-stage clinical programs | DJ |
Company Valuation: Basilea Pharmaceutica AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 484.7 | 545.8 | 422.9 | 501.2 | 672.1 | 911.7 | - | - |
| Change | - | 12.62% | -22.52% | 18.52% | 34.1% | 35.64% | - | - |
| Enterprise Value (EV) 1 | 552.8 | 630 | 473.9 | 472.6 | 585.2 | 754.5 | 694.3 | 688.9 |
| Change | - | 13.97% | -24.78% | -0.28% | 23.84% | 28.92% | -7.98% | -0.77% |
| P/E | -70.6x | 44.9x | 41x | 7.09x | 17.4x | 14.9x | 17.6x | 90.7x |
| PBR | - | - | -42.3x | 6.17x | 5.26x | 4.81x | 3.56x | 3.71x |
| PEG | - | -0x | -2.6x | 0x | -0.4x | 0.3x | -1.1x | -1.1x |
| Capitalization / Revenue | 3.27x | 3.69x | 2.68x | 2.4x | 2.89x | 3.34x | 3.19x | 4.33x |
| EV / Revenue | 3.73x | 4.26x | 3.01x | 2.27x | 2.52x | 2.76x | 2.43x | 3.28x |
| EV / EBITDA | 287x | 32.1x | 22.8x | 7.51x | 11x | 9.76x | 12.1x | 49.5x |
| EV / EBIT | 461x | 34.1x | 24.7x | 7.72x | 11.4x | 7.97x | 12x | 59.9x |
| EV / FCF | -16.8x | 168x | 35.9x | 6.51x | 9.88x | 8.88x | 12.1x | 52.2x |
| FCF Yield | -5.94% | 0.6% | 2.79% | 15.4% | 10.1% | 11.3% | 8.27% | 1.92% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.58 | 1.02 | 0.86 | 5.83 | 3.14 | 4.921 | 4.166 | 0.8095 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 148.1 | 147.8 | 157.6 | 208.5 | 232.4 | 273.3 | 285.8 | 210.3 |
| EBITDA 1 | 1.926 | 19.64 | 20.78 | 62.91 | 53.36 | 77.28 | 57.56 | 13.93 |
| EBIT 1 | 1.2 | 18.5 | 19.2 | 61.2 | 51.5 | 94.62 | 58.1 | 11.51 |
| Net income 1 | -6.8 | 12.15 | 10.5 | 77.6 | 40.2 | 68.15 | 57.8 | 6.412 |
| Net Debt 1 | 68.1 | 84.17 | 50.98 | -28.65 | -86.9 | -157.2 | -217.4 | -222.7 |
| Reference price 2 | 40.92 | 45.80 | 35.30 | 41.35 | 54.70 | 73.40 | 73.40 | 73.40 |
| Nbr of stocks (in thousands) | 11,844 | 11,918 | 11,980 | 12,121 | 12,288 | 12,420 | - | - |
| Announcement Date | 15/02/22 | 14/02/23 | 13/02/24 | 18/02/25 | 17/02/26 | - | - | - |
1CHF in Million2CHF
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 14.67x | 2.71x | 9.57x | -.--% | 1.08B | |
| 17.08x | 6.33x | 12.4x | 1.75% | 63.48B | |
| 30.03x | 7.96x | 26.08x | 0.05% | 54.55B | |
| 37.03x | 6.57x | 19.63x | 0.87% | 53.59B | |
| 35.05x | 3.37x | 14.55x | -.--% | 44.75B | |
| 48.28x | 5.55x | 30.42x | -.--% | 41.62B | |
| -19.33x | 186.93x | -20.57x | -.--% | 39.91B | |
| 30.28x | 7.94x | 20.6x | 0.4% | 32.47B | |
| 36.51x | 6.64x | 22.27x | -.--% | 26.7B | |
| 26.96x | 5.67x | 14.71x | -.--% | 23.36B | |
| Average | 25.66x | 23.97x | 14.97x | 0.31% | 38.15B | |
| Weighted average by Cap. | 26.52x | 25.17x | 15.66x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BSLN Stock
- Valuation Basilea Pharmaceutica AG
Select your edition
All financial news and data tailored to specific country editions
